- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00140088
Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Effectiveness and Safety of ALGRX 3268 in Pediatric Subjects.
Study Overview
Detailed Description
Management of pain due to minor procedures such as venipuncture or peripheral venous canulation still represents an unmet medical need, especially in pediatric setting. Current therapeutic products have a relatively delayed onset of analgesia of at least 10 minutes; moreover the most used products require application with at least 30-60 minutes prior to procedure. Development of ALGRX 3268 is aimed at addressing this unmet need in management of pain associated with needlestick procedures.
ALGRX 3268 (Previously known as PowderJect(R) Dermal Lidocaine) is used for local anesthesia to provide within 1-3 minutes painless needle or cathether insertion for blod drawing. ALGRX 3268 is a single-use disposable system, incorporating a drug cassette and glass cylinder into a single hand held device, with a button to actuate the system.
The purpose of this phase III, multicenter, prospective, randomized, double-blind, placebo-controlled study is to investigate the efficacy, safety and tolerability of ALGRX 3268 versus placebo in pediatric patients 3 to 18 years of age, who undergo venipuncture or peripheral venous canulation procedures. The trial will enroll approximate 504 evaluable subjects at centers located in the US.
Three age groups are enrolled: 3-7 years, 8-12 years, 13-18 years. Within each age group subjects are randomized to receive ALGRX 3268 0.5 mg/20 bar or pressure matched placebo. One to 3 minutes after administration of study treatment at the back of the hand or antecubital fosa, venipuncture is performed with a needle/Vacutainer, needle/syringe or "butterfly", at the discretion of the investigator.
Subjects 3-18 years are asked to assess pain on venipuncture using Wong-Baker FACES pain rating scale, anchored at 0 for "no hurt" and 5 for "hurts worst". Assessment of pain will be analyzed in each age group 3-7, 8-12, 13-18 and using Wong-Baker FACES pain rating scale.
Children in the middle (8-12) and older (13-18) age groups will also rate pain at the ACF and BOH using a 100 mm VAS anchored at 0 for "no pain" and at 100 for "extreme pain". Parent/legal guardian will evaluate child's level of pain on a 100 mm VAS anchored at 0, for "no pain", and at 100 for "extreme pain".
Safety ratings of skin are completed at 15 and 30 minutes following the procedure. AEs/SAEs will be monitored.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Connecticut Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatient children of either gender [M/F: 1:1] undergoing venipuncture or peripheral venous cannulation at the antecubital fossa or back of hand. Children must have sufficient cognitive skills to identify faces depicting extremes of pain on the Wong-Baker FACES Pain Rating Scale, (ages 3-12) and/or the extremes of pain on a 100 VAS (ages 8-18).
- Ages 3-7, 8-12, 13-18 years inclusive. Informed consent forms must have been approved by the appropriate IRB. Signed informed consent must have been granted by the parent/legal guardian and assent to participate should have been sought (either verbally or in writting) from each child.
- In females of childbearing potential who in the judgement of the investigator or designee were sexually active, a negative preganancy test must have been documented prior to enrollment. A negative urine preganancy test was required in all teenage girls over the age of 14 years. Surgically sterile females do not require a pregnancy test.
Exclusion Criteria:
- Previous history of allergic reactions to any local anesthetic. Any medical condition or instability that in the judgement of the investigator might have adversely impacted the conduct of the study and the collection of data.
- Subjects in whom the investigator determined that venipuncture could not be accomplished cleanly.
- Active local infection or other skin pathology on the dorsum of the hand. Subjects with tattos, surgical scars, ports, implantable devices or a skin condition that may have interfered with placement of study treatment or skin site assessments.
- Female subjects who were pregnant or lactating; females with a positive serum or urine pregnancy test; females of childbearing potential who were not using adequate contraception.
- Prior participation in an ALGRX 3268 study.
- Venipuncture at the proposed site within the prior 2 weeks (longer if bruising was apparent).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Child's rating of pain on venipuncture following administration of the study treatment.
|
Secondary Outcome Measures
Outcome Measure |
---|
Evaluation of pain due to venipuncture in each age group 3-7, 8-12 and 13-18.
|
Parent/legal guardian's rating of child's pain on an 100 VAS.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William Zempsky, MD, Connecticut Childrne's Medical Center
Publications and helpful links
General Publications
- Schmitz ML, Zempsky WT, Meyer JM. Safety and Efficacy of a Needle-free Powder Lidocaine Delivery System in Pediatric Patients Undergoing Venipuncture or Peripheral Venous Cannulation: Randomized Double-blind COMFORT-004 Trial. Clin Ther. 2015 Aug;37(8):1761-72. doi: 10.1016/j.clinthera.2015.05.515. Epub 2015 Jul 8.
- Zempsky WT, Bean-Lijewski J, Kauffman RE, Koh JL, Malviya SV, Rose JB, Richards PT, Gennevois DJ. Needle-free powder lidocaine delivery system provides rapid effective analgesia for venipuncture or cannulation pain in children: randomized, double-blind Comparison of Venipuncture and Venous Cannulation Pain After Fast-Onset Needle-Free Powder Lidocaine or Placebo Treatment trial. Pediatrics. 2008 May;121(5):979-87. doi: 10.1542/peds.2007-0814.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3268-3-003-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Procedural Pain
-
IRCCS Burlo GarofoloCompletedProcedural Pain ReliefItaly
-
Defense and Veterans Center for Integrative Pain...DepomedCompletedMinor Procedural PainUnited States
-
IWK Health CentreCompletedNeonatal Procedural Pain ResponseCanada
-
Beth Israel Deaconess Medical CenterRecruitingProcedural Pain | Pain Catastrophizing | Procedural AnxietyUnited States
-
University of UtahCompleted
-
University Hospital, BrestCompletedPrevention of the Procedural Pain in the NewbornFrance
-
Hamad Medical CorporationRecruitingProcedural Pain | Procedural AnxietyQatar
-
Nationwide Children's HospitalEnrolling by invitationProcedural Pain | Procedural AnxietyUnited States
-
Central Hospital, Nancy, FranceUnknownVirtual Reality | Procedural Pain | Procedural AnxietyFrance
-
University of YalovaRecruiting
Clinical Trials on ALGRX 3268
-
AlgoRx PharmaceuticalsCompleted
-
AlgoRx PharmaceuticalsCompleted
-
AlgoRx PharmaceuticalsCompleted
-
AlgoRx PharmaceuticalsCompletedPostoperative PainFormer Serbia and Montenegro
-
AlgoRx PharmaceuticalsCompletedPostoperative PainDenmark
-
AlgoRx PharmaceuticalsCompletedKnee Injuries | Arthroplasty, Replacement, KneeUnited States
-
Rigshospitalet, DenmarkCompleted